Get the Stockscreener App
6.58
1.79%
-0.12
Lyra Therapeutics Inc stock is traded at $6.58, with a volume of 24,144.
It is down -1.79% in the last 24 hours and down -26.03% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$6.70
Open:
$6.59
24h Volume:
24,144
Relative Volume:
0.04
Market Cap:
$8.72M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-4.4161
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
-17.23%
1M Performance:
-26.03%
6M Performance:
-28.01%
1Y Performance:
-57.04%
1-Day Range:
$6.32
$7.06
1-Week Range:
$6.32
$8.3685
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
6.58 | 10.71M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Can trapped investors hope for a rebound in Lyra Therapeutics Inc.Daily Technical Chart Pattern Analysis Report - Newser
Is a relief rally coming for Lyra Therapeutics Inc. holdersSwing Trade Timing with Daily Forecast - Newser
What are Lyra Therapeutics Inc. company’s key revenue driversDaily Trading Strategy To Watch Now - jammulinksnews.com
Real time scanner hits for Lyra Therapeutics Inc. explainedFree Price Action Based Buy Opportunity List - Newser
Is Lyra Therapeutics Inc. stock poised for growthSummary of Consistent Growth Stock Picks - Newser
Why Lyra Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Forecast Powered by AI Tools - Newser
What makes Lyra Therapeutics Inc. stock price move sharplySmart Trade Mapping with Entry Details - Newser
Is it time to cut losses on Lyra Therapeutics Inc.Breakout Screener With Alert Based Timing - Newser
Key resistance and support levels for Lyra Therapeutics Inc.Equity Performance Forecast Based on AI Models - Newser
Real time breakdown of Lyra Therapeutics Inc. stock performancePattern Detection for Entry Confirmation Enabled - metal.it
Competitive Positioning of Lyra Therapeutics Inc.: Is It Leading or LaggingMulti-Year Signal Summary and Entry Timing - Newser
Is Lyra Therapeutics Inc. stock reversal real or fakeTrading Opportunities Forecast by AI Insight - Newser
Buy Signal for Lyra Therapeutics Inc. Stock Key Technical Indicators to WatchWeekly Gain Forecast with Momentum Indicators - Newser
Should you wait for a breakout in Lyra Therapeutics Inc.Weekly Return Plan for Conservative Traders - Newser
Is Lyra Therapeutics Inc. stock overvalued or undervaluedDiscover high-impact stocks for growth - jammulinksnews.com
Should I hold or sell Lyra Therapeutics Inc. stock in 2025Achieve rapid returns with smart investment plans - jammulinksnews.com
What catalysts could drive Lyra Therapeutics Inc. stock higher in 2025Unlock real-time trading signals for gains - jammulinksnews.com
What are the latest earnings results for Lyra Therapeutics Inc.Achieve unparalleled market performance - jammulinksnews.com
Why is Lyra Therapeutics Inc. stock attracting strong analyst attentionFree Predictions - jammulinksnews.com
Published on: 2025-07-28 05:06:52 - jammulinksnews.com
How many analysts rate Lyra Therapeutics Inc. as a “Buy”Invest in stocks with strong fundamentals - jammulinksnews.com
How does Lyra Therapeutics Inc. compare to its industry peersGet expert insights on market-moving stocks - jammulinksnews.com
Will Lyra Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsProfitable Yet Secure Picks - Newser
How Interest Rate Changes Impact Lyra Therapeutics Inc. Stock PerformanceChart Based Entries - Newser
Lyra Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDefensive Stock Picks with Upside - Newser
When is Lyra Therapeutics Inc. stock expected to show significant growthOutstanding growth strategies - jammulinksnews.com
Has Lyra Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewTop Analyst Picks - Newser
How high can Lyra Therapeutics Inc. stock price go in 2025Free Bull & Bear Market Updates - jammulinksnews.com
Is Lyra Therapeutics Inc. a good long term investmentUnstoppable trading performance - Autocar Professional
What drives Lyra Therapeutics Inc. stock priceConsistent wealth multiplication - jammulinksnews.com
Lyra Therapeutics Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional
What analysts say about Lyra Therapeutics Inc. stockRobust financial gains - Autocar Professional
Lyra Therapeutics (LYRA) Proposes Sale of 846,744 Shares of Comm - GuruFocus
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):